Document:

Exhibit
10.1

 

EXECUTION VERSION

 

SIXTH AMENDMENT dated as of December 7, 2010 (this “Amendment”),
to the CREDIT AGREEMENT dated as of August 15, 2008, as heretofore amended (as
so amended, the “Credit Agreement”), among CEPHALON, INC., a Delaware
corporation, the LENDERS party thereto and JPMORGAN CHASE BANK, N.A., as
Administrative Agent.

 

WHEREAS,
the Lenders have agreed to extend credit to the Borrower under the Credit
Agreement on the terms and subject to the conditions set forth therein; and

 

WHEREAS,
the Borrower has requested that the Lenders amend certain provisions of the
Credit Agreement, and the Lenders whose signatures appear below, constituting
at least the Required Lenders, are willing to amend the Credit Agreement on the
terms and subject to the conditions set forth herein;

 

NOW,
THEREFORE, in consideration of the mutual agreements herein contained and other
good and valuable consideration, the sufficiency and receipt of which are
hereby acknowledged, the parties hereto hereby agree as follows:

 

SECTION 1.  Defined Terms.  Capitalized terms used but not otherwise
defined herein (including in the recitals hereto) have the meanings assigned to
them in the Credit Agreement.

 

SECTION 2.  Amendments to the Credit Agreement.  (a)  Section
1.01 of the Credit Agreement is hereby amended by inserting in the appropriate
alphabetical place the following new defined term:

 

“Specified
Investment” means (a) the purchase or other acquisition by the Borrower or
any Subsidiary (in a single transaction or a series of related transactions) (i)
resulting in ownership by the Borrower or any Subsidiary of up to 20% of the
common Equity Interests in a Person identified as “Martin” (the “Target”)
for up to $300,000,000 and (ii) of an exclusive license to use the Target’s or
an Affiliate of Target’s technology platform to develop products in therapeutic
areas of interest to Cephalon for up to $150,000,000, (b) any capital
contributions or loans or advances by the Borrower or any Subsidiary to any
Subsidiary of the funds to make the investments referred to in clause (a), and (c)
any subsequent transfer of Equity Interests in the Target or the exclusive
license referred to in clause (a)(ii) above from the Borrower or any Subsidiary
to any Subsidiary; provided that the definitive documentation for the
transactions referred to in clause (a) above shall have been executed and
delivered on or prior to January 31, 2011, and, at the time of and immediately
after giving effect to any such transactions, (x) no Default shall have occurred
and be continuing and (y) the Borrower shall be in compliance with the
covenants set forth in Sections 6.12, 6.13 and 6.14, in each case determined on
a pro  forma basis in a manner consistent with Section 1.04(b) solely
to give effect to the incurrence of

 

 

Indebtedness, if any, by
the Borrower or any Subsidiary in connection with such transactions.

 

(b)
 Section 6.04 of the Credit Agreement is
hereby amended by (i) deleting the “and” at the end of clause (z), (ii) replacing
the period at the end of clause (aa) with “; and” and (iii) adding the
following new clause:

 

(bb)  the Specified Investment.

 

SECTION 3.  Representations and Warranties.  The Borrower hereby represents and warrants
to the Administrative Agent and to each of the Lenders, as of the Amendment
Effective Date (as defined below), that:

 

(a)
 The execution, delivery and performance
by the Borrower of this Amendment have been duly authorized by all necessary
corporate or other organizational and, if required, stockholder or other
equityholder action.  This Amendment has
been duly executed and delivered by the Borrower and this Amendment and the
Credit Agreement, as amended by this Amendment, constitute legal, valid and
binding obligations of the Borrower, enforceable against it in accordance with
its terms, subject to applicable bankruptcy, insolvency, reorganization,
moratorium and other laws affecting creditors’ rights generally and to general
principles of equity, regardless of whether considered in a proceeding in
equity or at law.

 

(b)
 The representations and warranties of
the Borrower and the Subsidiary Loan Parties set forth in the Credit Agreement
and the other Loan Documents are true and correct in all material respects on
and as of the Amendment Effective Date, except in the case of any such
representation or warranty that expressly relates to an earlier date, in which
case such representation or warranty is true and correct in all material
respects on and as of such earlier date.

 

(c)
 On and as of the Amendment Effective
Date, after giving effect to this Amendment, no Default has occurred and is
continuing.

 

SECTION 4.  Effectiveness.  This Amendment shall become effective, as of
the date first above written, on the date (the “Amendment Effective Date”)
on which the Administrative Agent shall have received duly executed
counterparts hereof that, when taken together, bear the authorized signatures
of the Borrower and Lenders constituting at least the Required Lenders, provided
that the Administrative Agent shall have received all fees and other amounts
due and payable to it or any of its Affiliates on or prior to the Amendment
Effective Date, including reimbursement of all reasonable and documented
out-of-pocket expenses (including fees, charges and disbursements of counsel)
required to be reimbursed by the Borrower under the Credit Agreement.

 

SECTION 5.  Effect of Amendment.  (a)  Except as expressly set forth herein, this
Amendment shall not by implication or otherwise limit, impair, constitute a
waiver of or otherwise affect the rights and remedies of the Lenders or the
Administrative Agent under the Credit Agreement or any other Loan Document, and
shall not alter, modify, amend or in any way affect any of the terms,
conditions, obligations, covenants

 

2

 

or agreements contained in the Credit Agreement or
any other Loan Document, all of which are ratified and affirmed in all respects
and shall continue in full force and effect. 
Nothing herein shall be deemed to entitle any Loan Party to a consent
to, or a waiver, amendment, modification or other change of, any of the terms,
conditions, obligations, covenants or agreements contained in the Credit
Agreement or any other Loan Document in similar or different circumstances.

 

(b)
 On and after the Amendment Effective
Date, each reference in the Credit Agreement to “this Agreement”, “hereunder”, “hereof”,
“herein”, or words of like import, and each reference to the Credit Agreement
in any other Loan Document shall be deemed to be a reference to the Credit
Agreement as amended hereby.  This
Amendment shall constitute a “Loan Document” for all purposes of the Credit
Agreement and the other Loan Documents.

 

SECTION 6.  Applicable Law.  THIS AMENDMENT SHALL BE CONSTRUED IN
ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.

 

SECTION 7.  Counterparts.  This Amendment may be executed in
counterparts (and by different parties hereto on different counterparts), each
of which shall constitute an original but all of which, when taken together,
shall constitute a single contract. 
Delivery of an executed counterpart of a signature page of this
Amendment by facsimile or other electronic imaging shall be as effective as
delivery of a manually executed counterpart of this Amendment.

 

SECTION 8.  Severability.  Any provision of this Amendment held to be
invalid, illegal or unenforceable in any jurisdiction shall, as to such
jurisdiction, be ineffective to the extent of such invalidity, illegality or
unenforceability without affecting the validity, legality and enforceability of
the remaining provisions hereof; and the invalidity of a particular provision
in a particular jurisdiction shall not invalidate such provision in any other
jurisdiction.

 

SECTION 9.  Headings.  The Section headings used herein are for
convenience of reference only, are not part of this Amendment and shall not
affect the construction of, or be taken into consideration in interpreting,
this Amendment.

 

SECTION 10.  Administrative Agent’s Expenses.  Without limiting the Borrower’s obligations
under Section 9.03 of the Credit Agreement, the Borrower agrees to reimburse
the Administrative Agent for its reasonable and documented out-of-pocket
expenses in connection with this Amendment, including the reasonable fees,
charges and disbursements of Cravath, Swaine & Moore LLP, counsel for the
Administrative Agent.

 

3

 

SIGNATURE PAGE TO

SIXTH AMENDMENT TO

CEPHALON, INC. CREDIT
AGREEMENT

 

IN
WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly
executed by their respective authorized officers as of the date first above
written.

 

 

	
  Name
  of Party:

  	
  CEPHALON,
  INC.,

  
	
   

  	
   

  
	
   

  	
  by

  
	
   

  	
   

  	
  /s/
  Wilco Groenhuysen

  
	
   

  	
   

  	
  Name:  Wilco Groenhuysen

  
	
   

  	
   

  	
  Title:  Executive Vice President, Chief Financial
  Officer

  

 

 

	
  Name
  of Institution:

  	
  JPMORGAN
  CHASE BANK, N.A., individually and as Administrative Agent

  
	
   

  	
   

  
	
   

  	
  by

  
	
   

  	
   

  	
  /s/
  James A. Knight

  
	
   

  	
   

  	
  Name:  James A. Knight

  
	
   

  	
   

  	
  Title:  Vice President

  

 

 

SIGNATURE PAGE TO

SIXTH AMENDMENT TO

CEPHALON, INC. CREDIT AGREEMENT

 

 

	
  Name
  of Institution:

  	
  BANK
  OF AMERICA, N.A.

  
	
   

  	
   

  
	
   

  	
  by

  
	
   

  	
   

  	
  /s/
  Yinghua Zhang

  
	
   

  	
   

  	
  Name:  Yinghua Zhang

  
	
   

  	
   

  	
  Title:  Vice President

  

 

 

SIGNATURE PAGE TO

SIXTH AMENDMENT TO

CEPHALON, INC. CREDIT
AGREEMENT

 

 

	
  Name
  of Institution:

  	
  CITIZENS
  BANK OF PENNSYLVANIA

  
	
   

  	
   

  
	
   

  	
  by

  
	
   

  	
   

  	
  /s/
  Jonathan H. Sprogell

  
	
   

  	
   

  	
  Name:  Jonathan H. Sprogell

  
	
   

  	
   

  	
  Title:  Senior Vice President

  

 

 

SIGNATURE PAGE TO

SIXTH AMENDMENT TO

CEPHALON, INC. CREDIT
AGREEMENT

 

 

	
  Name
  of Institution:

  	
  DEUTSCHE
  BANK AG NEW YORK BRANCH

  
	
   

  	
   

  
	
   

  	
  by

  
	
   

  	
   

  	
  /s/
  Frederick W. Laird

  
	
   

  	
   

  	
  Name:  Frederick W. Laird

  
	
   

  	
   

  	
  Title:  Managing Director

  
	
   

  	
   

  
	
   

  	
  And

  
	
   

  	
   

  
	
  Name
  of Institution: (1)

  	
  DEUTSCHE
  BANK AG NEW YORK BRANCH

  
	
   

  	
   

  
	
   

  	
  by

  
	
   

  	
   

  	
  /s/
  Ming K. Chu

  
	
   

  	
   

  	
  Name:  Ming K. Chu

  
	
   

  	
   

  	
  Title:  Vice President

  

 

(1)
 For any Lender requiring a second signature
line.

 

 

SIGNATURE PAGE TO

SIXTH AMENDMENT TO

CEPHALON, INC. CREDIT
AGREEMENT

 

 

	
  Name
  of Institution:

  	
  U.S.
  Bank National Association

  
	
   

  	
   

  
	
   

  	
  by

  
	
   

  	
   

  	
  /s/
  Jennifer Hwang

  
	
   

  	
   

  	
  Name:  Jennifer Hwang

  
	
   

  	
   

  	
  Title:  Vice President

  

 

 

	
  Name
  of Institution:

  	
  Wells
  Fargo Bank, N.A.

  
	
   

  	
   

  
	
   

  	
  by

  
	
   

  	
   

  	
  /s/
  John M. Fessick

  
	
   

  	
   

  	
  Name:  John M. Fessick

  
	
   

  	
   

  	
  Title:  Senior Vice Presidentex10_1.htm

Exhibit 10.1

 

 

CONSULTING AGREEMENT

This CONSULTING AGREEMENT is made and entered into as of the 9th day of December, 2010 by and between NanoViricides, Inc., a publicly owned Nevada corporation ("NanoViricides" or “Company”) and Amanda Schuon (the "Business Advisor").

WITNESSETH

WHEREAS, the Business Advisor has agreed to and has served as a business advisor to NanoViricides since on or about June 1, 2005 as a public relations advisor and publicist, including handling shareholder communications, reviewing, revising, drafting and distributing press releases and advising the Company regarding same, and continues to do so (the “Services”);

WHEREAS, the Business Advisor has at no point ever  been compensated for the Services and NanoViricides desires to compensate the Business Advisor on the terms and conditions hereinafter set forth.

 

NOW THEREFORE, in consideration of, and for the mutual promises and covenants contained herein, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties agree as follows:

1. PURPOSE. NanoViricides hereby engages the Business Advisor on a non-exclusive basis for the term specified in this Agreement to render the Services upon the terms and conditions set forth herein.

2. REPRESENTATIONS OF THE BUSINESS ADVISOR AND NANOVIRICIDES. The Business Advisor represents and warrants to NanoViricides that it is free to enter into this Agreement and the business consulting and advisory services to be provided pursuant to this Agreement are, not in conflict with any other contractual or other obligation to which the Business Advisor is, bound. NanoViricides acknowledges that that nothing herein contained shall be construed to limit or restrict the Business Advisor in conducting such business with respect to others, or rendering such services to others.

 

3. COMPENSATION.  NanoViricides shall pay Business Advisor for the Services a total of 50,000 shares of validly issued shares of NanoViricides’ common stock, par value $0.001 per share, registered pursuant to a registration statement on Form S-8.

 

  

  

  

 

4. INDEMNITY.  NanoViricides agrees to indemnify and hold Business Advisor, its agents, employees, and representatives, free and harmless from and against any and all claims, losses, damages, costs, or actions arising from, out of, or relating to this Agreement, the performance of the Services, or any other act or omission of NanoViricides, its officers, agents, directors, employees, representatives, successors, or assigns hereunder.  Said indemnification and hold harmless includes reasonable attorney fees and costs incurred by Company regarding any such claims, losses, damages, costs, or actions.

 

5. AGREEMENTS OF NANOVIRICIDES AND BUSINESS ADVISOR.  The Company agrees that:

 

(a)        At the commencement of the Services and at the time of the provision of the Services during the term of this Agreement, NanoViricides will furnish Business Advisor and its agents and counsel with all information concerning NanoViricides that Business Advisor and its agents reasonably deem appropriate and agrees to provide Business Advisor and its agents with reasonable access to NanoViricides’ officers, directors, accountants, counsel, Business Advisors and other appropriate agents and representatives. NanoViricides acknowledges the Business Advisor and its agents may rely upon the completeness and accuracy of information and data furnished to any of them by or on behalf of NanoViricides; provided, however, that Business Advisor shall not provide any information in any form that has not been approved by NanoViricides and shall not make any statements concerning NanoViricides’ business, financial condition, operations or projected financial results which have not been approved in advance by NanoViricides.

 

(b)        All payments of compensation to Business Advisor shall not cause NanoViricides to violate any law or regulation applicable to NanoViricides.

 

(c)        This Agreement had been, and the Services contemplated hereby at the time of the commencement and consummation thereof, shall be duly authorized by NanoViricides.

 

(d)        NanoViricides agrees that no advice or recommendations rendered or summarized, excerpted from or otherwise referred to without Business Advisor’s prior written consent other than to NanoViricides’ personnel, accountants, counsel, investment advisors and others with which NanoViricides has a relationship unless required by law.  Business Advisor may not be otherwise referred to by NanoViricides without Business Advisor’s prior written consent or unless required by law.

 

  

  

  

 

6. MATERIAL NON-PUBLIC INFORMATION.

 

(a)           In connection with the performance by Business Advisor of the Services, NanoViricides may provide Business Advisor certain information and data which is material non-public information and which NanoViricides wishes to keep confidential, including, but not limited to, information regarding NanoViricides’ governance, board of directors, management, plans, strategies, business, finances or operations, including information relating to financial statements and other financial information, evaluations, projections, plans, programs, customers, plants, equipment and other assets, products, processes, manufacturing, marketing, research and development, know-how and technology, intellectual property and trade secrets and information which Company has obtained from third parties and with respect to which NanoViricides is obligated to maintain confidentiality (collectively, “Confidential Information”).  Confidential Information may include information or materials in oral, written, pictorial, magnetic or graphic form or maintained or transferred in any other media.

 

(b)           Except as provided in this Section 9, Business Advisor will not (a) disclose any Confidential Information to third parties or use any Confidential Information in each instance without securing the prior written consent of NanoViricides or (b) engage in any purchases, sales or other transactions involving NanoViricides’ securities while in possession of material non-public information relating to NanoViricides. Business Advisor further acknowledges that any violation of clause (b) of this Section 6(b) may constitute a violation of federal or state securities laws.

 

(c)           Confidential Information does not include information which (a) is or becomes known publicly known through no fault or action on the part of Business Advisor; (b) Business Advisor can show by documentary evidence that it (i) has learned from a third party who it believes in good faith is entitled to disclose it; (ii) already known to Business Advisor before disclosure by NanoViricides; or (iii) independently developed by Business Advisor without access to any Confidential Information.

 

(d)           Business Advisor shall be responsible for the conduct of its directors, officers, subsidiaries, affiliates, Business Advisors, employees and representatives regarding the confidentiality and use of the Confidential Information. Business Advisor shall only disclose the Confidential Information to employees, Business Advisors and representatives that are bound by confidentiality obligations that are at least as restrictive as the terms of this Agreement and that have a need to review the Confidential Information in order to enable Business Advisor to evaluate NanoViricides. Any disclosure of Confidential Information to Business Advisor shall not be deemed to grant a license or right to Business Advisor to use Confidential Information for any purpose other than as explicitly set forth in this Agreement.

 

  

  

  

 

(e)           In the event that any Confidential Information is required to be produced by Business Advisor pursuant to legal process, Business Advisor shall give NanoViricides notice of such legal process within a reasonable time, but not later than ten (10) business days prior to the date such disclosure is to be made, unless Business Advisor has received less notice, in which event Business Advisor shall notify the Company as promptly as practicable.  NanoViricides shall have the right to object to any such disclosure, and if NanoViricides objects in a timely manner so that Business Advisor is not subject to penalties for failure to make such disclosure, Business Advisor shall not make any disclosure until there has been a court determination on NanoViricides’ objections.  If disclosure is required by a court order, final beyond right of review, or if NanoViricides does not object to the disclosure, Business Advisor shall make disclosure only to the extent that disclosure is unequivocally required by the court order, and Business Advisor will exercise reasonable efforts at NanoViricides’ expense, to obtain reliable assurance that confidential treatment will be accorded the Confidential Information.

 

(f)           Business Advisor agrees that any violation or threatened violation of any of the provisions of this Agreement shall cause immediate and irreparable harm to NanoViricides. In the event of any breach or threatened breach of this Agreement, Business Advisor consents to the entry of preliminary and permanent injunctions by a court of competent jurisdiction prohibiting Business Advisor from any violation or threatened violation of such provisions and compelling Business Advisor to comply with such provisions. This Section 9(f) shall not affect or limit, and the injunctive relief provided in this Section 9 shall be in addition to, any other remedies available to NanoViricides at law or in equity for any such violation.

 

7. SURVIVAL OF CERTAIN PROVISIONS.  The provisions of Sections 4 and 5 of this Agreement shall survive the termination of this Agreement and shall remain operative and in full force and effect regardless of any termination or expiration of this Agreement, and shall be binding upon, and shall inure to the benefit of, any successors, assigns, heirs and personal representatives of NanoViricides, Business Advisor, and any and all Indemnified Persons.

 

8. NOTICES.  All notices provided for in this Agreement shall be in writing signed by the party giving such notice, and delivered personally or sent by overnight courier service which obtains evidence of delivery, or registered or certified mail, return receipt requested, or by facsimile transmission or similar means of communication if receipt is confirmed or if transmission of such notice is confirmed by mail as provided in this Section 11.  Notices shall be deemed to have been received on the date of personal delivery or the date delivery is refused.  Notices shall be sent to any party to the attention of the person who executed this Agreement on behalf of such party at such party’s address or telecopier number set forth on the signature page of this Agreement. Either party may, by like notice, change the person, address or telecopier number to which notice shall be sent.

 

  

  

  

 

9. ENTIRE AGREEMENT.  This Agreement constitutes the entire agreement of the parties, superseding and terminating any and all prior or contemporaneous oral and written agreements, understandings or letters of intent between or among the parties with respect to the subject matter of this Agreement.  No part of this Agreement may be modified or amended, nor may any right be waived, except by a written instrument which expressly refers to this Agreement, states that it is a modification or amendment of this Agreement and is signed by the parties to this Agreement, or, in the case of waiver, by the party granting the waiver.  No course of conduct or dealing or trade usage or custom and no course of performance shall be relied on or referred to by any party to contradict, explain or supplement any provision of this Agreement, it being acknowledged by the parties to this Agreement that this Agreement is intended to be, and is, the complete and exclusive statement of the agreement with respect to its subject matter.  Any waiver shall be limited to the express terms thereof and shall not be construed as a waiver of any other provisions or the same provisions at any other time or under any other circumstances.

 

10. CONSTRUCTION.  This Agreement shall be governed by, and constructed in accordance with, the laws of the State of Nevada as applied to contracts made and performed in such State without regard to principles of conflicts of law. NanoViricides and Business Advisor each hereby irrevocably submits to the jurisdiction of the federal and state courts located in New York County, New York in connection with any suit, action, or proceeding related to this Agreement or any of the matters contemplated hereby, irrevocably waives any defense of lack of personal jurisdiction and irrevocably agrees that all claims in respect of any such suit, action or proceeding may be heard and determined in any such court. NanoViricides and Business Advisor each irrevocably waives, to the fullest extent it may effectively do so under applicable law, any objection which it may now or hereafter have to the laying of venue of any such suit, action or proceeding brought in any such court and any claim that any such suit, action or proceeding brought in any such court had been brought in an inconvenient forum.

 

11. SEVERABILITY.  Any determination that any provision of this Agreement may be, or is unenforceable shall not affect the enforceability of the remainder of this Agreement.

 

12. HEADINGS.  The paragraph headings in this Agreement have been inserted as a matter of convenience of reference and are not part of this Agreement.

 

13. COUNTERPARTS.  This Agreement may be executed in two or more counterparts and by facsimile, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.

 

14. THIRD PARTY BENEFICIARIES.  This Agreement has been and is made solely for the benefit of the Company and Business Advisor (including other Indemnified Persons described herein) and their respective successors and assigns, and no other person shall acquire or have any right under or by virtue of this Agreement

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth above.

 

	
NANOVIRICIDES, INC.

 

By: _______________________________

	
 

 

_________________________________

	
Name: Eugene Seymour, MD, MPH

	
AMANDA SCHUON

	
Title: Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}]]